⌘K

Home/Filings/4/0001628280-22-016731

4//SEC Filing

BRANCACCIO JOHN P 4

Accession 0001628280-22-016731

CIK 0001213037other

View on SEC.gov Company Profile

Filed

Jun 8, 8:00 PM ET

Accepted

Jun 9, 7:48 PM ET

Size

22.5 KB

Accession

0001628280-22-016731

Insider Transaction Report

Form 4

Period: 2022-06-09

Cardiff Oncology, Inc.CRDF

BRANCACCIO JOHN P

Director

Transactions

Other
Stock Options
2022-06-09+223→ 125,317 total
Exercise: $516.96From: 2016-03-17Exp: 2024-06-09→ Common Stock (223 underlying)
Other
Stock Options
2022-06-09+195→ 125,317 total
Exercise: $316.08From: 2014-12-11Exp: 2024-06-09→ Common Stock (195 underlying)
Other
Stock Options
2022-06-09+28,858→ 125,317 total
Exercise: $2.60From: 2021-06-17Exp: 2024-06-09→ Common Stock (28,858 underlying)
Other
Stock Options
2022-06-09+44,734→ 125,317 total
Exercise: $2.48From: 2020-06-20Exp: 2024-06-09→ Common Stock (44,734 underlying)
Other
Stock Options
2022-06-09+26,800→ 125,317 total
Exercise: $2.50From: 2022-06-09Exp: 2024-06-09→ Common Stock (26,800 underlying)
Other
Stock Options
2022-06-09+22,000→ 125,317 total
Exercise: $7.98From: 2022-06-09Exp: 2024-06-09→ Common Stock (22,000 underlying)
Other
Stock Options
2022-06-09+755→ 125,317 total
Exercise: $21.60From: 2019-01-23Exp: 2024-06-09→ Common Stock (755 underlying)
Other
Stock Options
2022-06-09+223→ 125,317 total
Exercise: $372.96From: 2017-01-04Exp: 2024-06-09→ Common Stock (223 underlying)
Other
Stock Options
2022-06-09+530→ 125,317 total
Exercise: $51.84From: 2018-10-04Exp: 2024-06-09→ Common Stock (530 underlying)

Footnotes (3)

[F1]In connection with the Reporting Person's departure from the Board of Directors, the Compensation Committee accelerated the vesting of 26,800 stock options to June 9, 2022 from March 9, 2023. In addition, the Compensation Committee extended the expiration date of the stock options to June 9, 2024.
[F2]In connection with the Reporting Person's departure from the Board of Directors, the Compensation Committee accelerated the vesting of 22,000 stock options to June 9, 2022 from June 10, 2022. In addition, the Compensation Committee extended the expiration date of the stock options to June 9, 2024.
[F3]Expiration date of the stock options was extended to June 9, 2024.

Documents

1 file

4
wf-form4_165481851971252.xmlPrimary
FORM 4

Issuer

Cardiff Oncology, Inc.

CIK 0001213037

Entity typeother

Related Parties

1

filerCIK 0001276551

Filing Metadata

Form type: 4
Filed: Jun 8, 8:00 PM ET
Accepted: Jun 9, 7:48 PM ET
Size: 22.5 KB

View on SEC.gov